1,376 Amgen Inc. $AMGN Shares Bought by Confluence Wealth Services Inc.

Confluence Wealth Services Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,976 shares of the medical research company’s stock after purchasing an additional 1,376 shares during the quarter. Confluence Wealth Services Inc.’s holdings in Amgen were worth $7,998,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Moneco Advisors LLC increased its holdings in shares of Amgen by 5.5% in the 3rd quarter. Moneco Advisors LLC now owns 4,643 shares of the medical research company’s stock worth $1,957,000 after buying an additional 242 shares during the last quarter. Mesirow Financial Investment Management Inc. raised its position in shares of Amgen by 2.3% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 14,846 shares of the medical research company’s stock valued at $6,258,000 after buying an additional 328 shares in the last quarter. Woodley Farra Manion Portfolio Management Inc. lifted its holdings in shares of Amgen by 4.1% in the 3rd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 15,509 shares of the medical research company’s stock valued at $6,537,000 after acquiring an additional 613 shares during the last quarter. 626 Financial LLC bought a new position in shares of Amgen in the 3rd quarter valued at about $222,000. Finally, Csenge Advisory Group lifted its holdings in shares of Amgen by 1.2% in the 3rd quarter. Csenge Advisory Group now owns 10,491 shares of the medical research company’s stock valued at $4,422,000 after acquiring an additional 129 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of several recent research reports. Wells Fargo & Company lifted their price target on Amgen from $430.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 4th. TD Cowen upped their price objective on Amgen from $452.00 to $531.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Cantor Fitzgerald raised their price objective on Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. Morgan Stanley lifted their target price on Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. Finally, Barclays boosted their target price on Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $422.76.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $465.23 on Wednesday. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a market capitalization of $251.65 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 3.25 and a beta of 0.43. The firm’s 50-day moving average is $423.79 and its 200 day moving average is $379.39.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm earned $5.64 earnings per share. Research analysts predict that Amgen Inc. will post 23.33 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio is presently 58.47%.

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.